Immunoglobulin E (IgE) Background {#S1}
=================================

Immunoglobulin E is responsible for the pathogenesis of many allergic diseases including asthma. The primary role of IgE is defense against parasitic disease such as helminthes and protozoa ([@B1]). IgE, like all immunoglobulins, is composed of two light chains and two identical heavy chains ([@B2]). The heavy chain for IgE is epsilon. IgE is a monomer and consists of four constant regions. The constant region, C-epsilon-3, binds to both the low- and high-affinity IgE receptor. Production of IgE requires two signals between T cells and B cells to override the default production of IgM by plasma cells ([@B3]). The first signal involves interleukin-4 (IL-4) and interleukin-13 (IL-13) release by T helper type 2 (Th2) cells, mast cells, and basophils interacting with their respective receptors on the B cell. The second signal is the interface between the B cell CD40 and the T cell CD40 ligand (CD154).

Immunoglobulin E functions *via* its high- and low-affinity receptors on mast cells, basophils, and other cells ([@B4]). The high-affinity receptor for IgE is Fc-epsilon-RI expressed on mast cells and basophils. When bound with IgE subsequent cross-linking leads to activation of the cell and release of preformed mediators and the production of other inflammatory cytokines. The inflammatory mediators released by mast cells and basophils include histamine, tryptases, tumor necrosis factor-alpha, leukotrienes, and prostaglandins. In addition, the production of the Th2 cytokines IL-4, IL-5, and IL-13 further initiate late-phase inflammation and promotes more IgE production. The low-affinity receptor Fc-epsilon-RII (CD23) in its inducible form is present on B cells, T cells, dendritic cells, monocytes, macrophages, neutrophils, eosinophils, intestinal epithelial cells, and platelets ([@B5], [@B6]). The low-affinity receptor helps regulates IgE synthesis and has a role in antigen presentation ([@B5], [@B6]).

Anti-IgE Antibody (Omalizumab) {#S2}
==============================

Omalizumab is a recombinant humanized immunoglobulin (IgG1) monoclonal antibody that binds IgE with high affinity developed for the treatment of allergic diseases ([@B7]). Omalizumab binds to the same C-epsilon-3 region that interacts with the IgE receptors forming complexes with free IgE preventing its interaction with these receptors ([@B8]). The omalizumab-IgE complexes are subsequently cleared by the hepatic reticuloendothelial system. Omalizumab is specific to IgE and does not bind to IgG or IgA. An important property of omalizumab is that it cannot bind to the IgE receptors or to IgE already attached to Fc-epsilon-RI, and therefore does not interact with cell-bound IgE or activate mast cells or basophils. Administration of omalizumab results in a rapid and significant decrease in free IgE levels. Due to this dramatic decrease in circulating IgE omalizuamb subsequently decreased the expression of the high affinity FcεRI receptor on the surface of both mast cells and basophils ([@B9]).

Omalizumab's Effect on Eosinophils {#S3}
==================================

In a pooled analysis of over 2,200 patients, omalizumab treatment reduced blood eosinophil counts which correlated with the reduction seen in free IgE ([@B10]). In asthmatic patients, two studies evaluated the effect of omalizumab on sputum eosinophils and bronchial biopsies. The first study by Djukanović et al. examined induced sputum and bronchial biopsies on 45 moderate to severe asthma patients with baseline sputum eosinophils ≥2% ([@B11]). Omalizumab treatment for 16 weeks reduced mean sputum eosinophils from 6.6 to 1.7%, while the reduction in the placebo group was only 8.5 to 7.0%. In the submucosal bronchial biopsies median eosinophil counts decreased from 8.0 to 1.5 cells/mm^2^ with omalizumab treatment while the counts were 6.3 to 6.4 cells/mm^2^ in the placebo group. There was a weak correlation with the reduction in submucosal eosinophils and reduction in cells producing IL-4. Van Rensen et al. studied the effects of omalizumab on allergen challenge with 25 atopic asthmatics ([@B12]). In their study, omalizumab decreased sputum eosinophils from 4 to 0.5% and bronchial biopsy eosinophil count from 15 to 2 cells/0.1 mm^2^.

One proposed mechanism for the reduction of eosinophils is by inducing eosinophil apoptosis. Nineteen patients with allergic asthma were treated 3 months of omalizumab ([@B13]). A marker of eosinophil apoptosis (annexin V) was increased in those patients treated with omalizamab and annexin-positive eosinophils were increased compared to baseline. In addition, cellular production of GM-CSF, used for eosinophil growth and survival, was decreased.

Asthma {#S4}
======

In the United States and worldwide, omalizumab is approved for use in patients 6 years of age and older with moderate-to-severe persistent perennial asthma ([@B14]). In patients with moderate-to-severe asthma, multiple studies have demonstrated that treatment with omalizumab (compared with placebo) decreases the incidence of exacerbations and significantly reduces the dose of inhaled or oral glucocorticoids required to control symptoms. In two studies of pooled data omalizumab reduced emergency room, asthma-related outpatient visits, and hospitalizations ([@B15], [@B16]). Several studies have examined omalizumab therapy in children. These studies demonstrated reduced exacerbations, asthma symptoms, inhaled corticosteroid (ICS) doses, daily systemic corticosteroid dose, and hospitalizations with omalizumab therapy ([@B17]--[@B19]). In 2014, a meta-analysis of 25 randomized trials of patients with moderate or severe asthma requiring inhaled glucocorticoids, omalizumab reduced the risk of experiencing an exacerbation from 26 to 16% over 16 to 60 weeks of treatment ([@B20]). In addition, omalizumab reduced the risk of hospitalization for asthma from 3 to 0.5% over 28 to 60 weeks as well as decreased the amount of ICSs needed for asthma control. In this analysis, subjects receiving omalizumab were more likely to be able to completely withdraw inhaled glucocorticoids compared with those receiving placebo (40 versus 21%). However, omalizumab did not appear to increase the likelihood that subjects could discontinue oral glucocorticoids or consistently improve lung function in this meta-analysis.

Predictors of Response to Omalizumab in Asthma Patients {#S5}
=======================================================

Asthma is a heterogenous disease with several different phenotypes. When based on inflammatory markers the Th~2~ pattern is the most common. The EXTRA omalizumab study evaluated 850 patients with severe perennial allergic asthma divided into low- and high-biomarker groups (F~ENO~, blood eosinophils, and serum periostin) ([@B21]). Patients in the high eosinophil group (≥260/μL) had a greater reduction in exacerbations with omalizumab treatment than those in the low group (\<260/μL). In a pediatric trial of omalizumab to prevent fall asthma exacerbations during the run in period patients those who had an exacerbation had a higher serum eosinophil count (350 cells/μL) compared to those without an exacerbation (280 cells/μL) ([@B22]). A 24-week, multicenter, parallel group, double-blind, randomized, placebo controlled trial on patients with symptomatic asthma despite ICSs evaluated exacerbation rates with 6 months of anti-IgE therapy ([@B23]). In a subgroup analysis, patients with a baseline eosinophil count of ≥300/mL treated with omalizumab had a reduction in protocol-defined exacerbations by nearly 60% compared to placebo. When using the exacerbations defined by ATS/ERS criteria, the rate was reduced by 45% with omalizumab treatment. In those patients with the low baseline eosinophil counts, no improvement was noted in protocol defined exacerbation. There are limited characteristics that predict a positive response to omalizumab therapy for asthma but findings suggest that patients with a higher baseline serum eosinophil count may have a better clinical outcome.

Chronic Urticaria {#S6}
=================

Urticaria and/or angioedema that occurs daily or near daily for more than 6 weeks has been termed chronic idiopathic urticaria (CU) or chronic spontaneous urticaria (CSU). First-line therapy, oral H1 antihistamines are effective for 50--60% of these patients ([@B24]). The initial proof-of-concept study involved 90 patients with antihistamine refractory CSU treated with a single administration of three different doses of omalizumab, 75, 300, or 600 mg versus placebo ([@B25]). Only the 300 and 600 mg doses demonstrated improvement in the urticaria scores 4 weeks after treatment and there was not a significant difference in efficacy between these doses. This led to three large, phase III, randomized, double-blind, placebo controlled studies, Asteria I, Asteria II, and Glacial ([@B26]--[@B28]). These studies evaluated patients aged 12--75 with CSU that was refractory to oral H1-antihistamines.

In the Asteria I trial, 318 patients were randomized to one of three different doses of omalizumab (75, 150, and 300 mg) or placebo every 4 weeks for 24 weeks after failing licensed doses of H1-antihistamine therapy ([@B26]). Within the first week, the 300 mg dose improved urticaria compared to placebo. At 12 weeks, all three omalizumb doses significantly reduced patient's symptoms at 12 weeks compared to placebo. By week 12, 52% of the high-dose omalizumab patients were well controlled and 36% completely controlled. In addition, the 300 mg dose improved associated angioedema symptoms.

The Asteria II trial was similar in design with the same doses of omalizumab or placebo and enrolled 323 patients with CSU who remained symptomatic despite H1-antihistamine therapy ([@B27]). In this study, patients were treated for only 12 weeks compared to 24 in the Asteria I. At the end of the study, the patients on 150 and 300 mg doses of omalizumab demonstrated significant improvements in symptom scores and number of hives compared to placebo with 53% of the group receiving 300 mg of omalizumab becoming hive free and 44% free from both hives and itching.

The Glacial trial had a significant difference compared to the two Asteria trials. These patients all failed H1-antihistamines up to four times licensed doses plus patients were allowed to have been on an H2-blocker and/or leukotriene antagonist ([@B28]). In this study, 335 patients were randomized to either 300 mg of omalizumab or placebo monthlym for 24 weeks of treatment with 16-week follow-up. This study demonstrated the effectiveness of 300 mg omalizumab monthly in reducing urticarial lesions and symptoms after 12 weeks of therapy which was sustained for the 24 weeks of therapy.

In a review of over 900 patients with CSU symptomatic despite conventional therapy omalizumab improved symptoms in 65% with complete resolution in 40%. The improvement was noted in a just a few days in a subset of these patients ([@B29]). Omalizumab has also improved symptoms in patients with different types of physical urticarias, including solar, cold, localized heat, cholinergic, dermatographic, and pressure ([@B30]--[@B37]). In successfully treated patients with CSU or with physical uriticaria discontinuing therapy may lead to, relapse within a few weeks. Retreatment with omalizumab was effective resolving those symptoms ([@B38]).

Several associations such as the American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma & Immunology, European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum, and the World Allergy Organization have recommended the use of omalizumab for CU in their urticaria guidelines ([@B39], [@B40]). In March of 2014, the US Food and Drug Administration approved the use of omalizumab in chronic urticaria patients 12 years and older who remain symptomatic despite H1 antihistamines.

The exact mechanisms of how omalizumab works in CU are unclear. In a subset of patients, IgG autoantibodies against FcεRI, IgE, or both may exist ([@B41]). Since omalizumab decreases the free IgE available with subsequent down-regulation of the FcεRI receptor, it was natural to postulate that omalizumab's effects might be due to decreasing the targets for these autoantibodies. However, no differences in effectiveness have been found in patients with or without the autoantibodies. Furthermore, analysis of previous data suggests that it takes time to significantly decrease the expression of the high affinity IgE receptors on either basophils (2 weeks) or mast cells (10 weeks); whereas a therapeutic effect within 1 week is noted in some patients ([@B42], [@B43]). Another possible mechanism is that IgE antibodies against autoallergens are present, and omalizumab reduces the level of these autoantibodies. Similar autoantibodies have been noted in patients with systemic lupus erythematosus contributing to the pathogenesis of that disease and similar autoimmune disorders ([@B44]).

Atopic Dermatitis {#S7}
=================

Atopic dermatitis is another potential allergic target for anti-IgE therapy. Atopic dermatitis has been treated with omalizumab in several case series of both adult and pediatric patients, but results have been mixed. In a small series of seven pediatric patients with severe atopic dermatitis clinical improvement was noted 3 to 6 months after starting therapy and all patients had improvement after 12 months of therapy ([@B45]). Heil et al. performed a randomized, placebo-controlled, double-blind pilot study on 20 atopic dermatitis patients ([@B46]). Patients were randomized to omalizumab (13) or placebo (7) treatments for 16 weeks. At the end of the study, omalizumab reduced free IgE, surface IgE, and FceRI expression. Despite these changes, no significant improvement was noted with omalizumab therapy on clinical symptoms of atopic dermatitis. Iyengar et al. performed another randomized, double-blind, placebo-controlled study of eight patients (four omalizumab, four placebo) with severe refractory atopic dermatitis ([@B47]). After 24 weeks of therapy, omalizumab decreased levels of allergic inflammatory mediators but clinical symptoms were comparable between the omalizumab and placebo groups. A recent meta-analysis included the previously mentioned randomized studies as well as 13 case series evaluating the effectiveness of omalizumab in treating atopic dermatitis ([@B48]). There was no concrete evidence that omalizumab was effective in treating atopic dermatitis. Despite that conclusion, it was noted that 43% of patients improved clinically with omalizumab. There may be specific types of patients who are more responsive than others based on multiple variables, age, baseline IgE level, atopic status, or presence of filaggrin mutation ([@B49]).

Allergic Rhinitis {#S8}
=================

Allergic rhinitis is another potential target for anti-IgE therapy. An early study in the United States evaluated 536 ragweed allergic patients at 25 different sites ([@B50]). This randomized, double-blind, placebo-controlled study evaluated several doses of omalizumab (50, 150, and 300 mg) and placebo administered every 3--4 weeks just prior to and during ragweed season. Patients treated with 300 mg of Omalizumab had significantly lower rhinitis symptoms. Those treated with the 300 mg dose of omalizumab had better quality of life scores than the other groups and did not decline during the peak ragweed season. A follow-up open-labeled study of 300 mg of omalizumab therapy every 3--4 weeks demonstrated that the therapy is well tolerated without any significant immunologic reactions ([@B51]). Further studies demonstrated omalizumab's effectiveness in reducing symptoms and rescue medication usage in patients with allergic rhinitis to ragweed, birch, cedar, and perennial allergens ([@B52]--[@B58]).

A meta-analysis published in 2014 retrieved 352 citations with 78 articles eligible for review ([@B59]). Of those studies, 11 qualified for evaluation with a total of 2,870 patients treated for seasonal or perennial allergic rhinitis. Omalizumab significantly reduced both daily nasal symptoms and daily nasal rescue medication usage. No significant adverse events were reported.

Allergen Immunotherapy {#S9}
======================

Allergen immunotherapy has been used for 100 years for the management of allergic disorders and is the only antigen-specific immunomodulatory treatment. The addition of omalizumab to standard maintenance-dose immunotherapy was evaluated in 221 pediatric patients sensitized to birch and grass pollen ([@B60]). During birch season, the addition of omalizumab reduced symptoms by 48% compared to birch SCIT alone. Similar results were seen in grass season, with a 57% decrease in symptoms with the addition of omalizumab to grass immunotherapy compared to grass immunotherapy alone. When these findings were further analyzed for the grass pollen--allergic children, the groups treated with omalizumab plus immunotherapy had significantly diminished rescue medication use and number of symptomatic days compared to omalizumab or immunotherapy alone ([@B61]). Casale et al. evaluated omalizumab starting 9 weeks before rush immunotherapy followed by 12 weeks of therapy ([@B62]). Overall, in ragweed-allergic patients the combination of omalizumab and immunotherapy showed a significant improvement in severity scores during the ragweed season compared with those receiving immunotherapy alone after rush immunotherapy buildup. Overall, these findings demonstrate that combined treatment with omalizumab and immunotherapy is more effective than omalizumab or immunotherapy alone.

Immunotherapy for allergens carries a risk of anaphylaxis with each administration. In those patients treated with rush ragweed immunotherapy, omalizumab added to immunotherapy had fewer adverse events than those receiving immunotherapy alone. The addition of omalizumab to SCIT resulted in a decrease in risk of anaphylaxis caused by immunotherapy by fivefold ([@B62]). In asthma patients, the use of omalizumab in conjunction with SCIT resulted in fewer systemic reactions (13.5 versus 26.2% for placebo) ([@B63]). The use of omalizumab in conjunction with venom immunotherapy in a few patients demonstrated conflicting results in preventing systemic reactions caused by immunotherapy ([@B64], [@B65]). Recently, the use of oral immunotherapy for food allergy noted benefit in patients with milk, egg, and peanut allergy. The data suggest that omalizumab may facilitate oral desensitization to peanut and milk ([@B66], [@B67]). The addition of omalizumab has allowed some children to successfully receive oral immunotherapy to multiple foods simultaneously, including milk, egg, peanut, wheat, soy, and tree nuts ([@B66]--[@B69]). The addition of omalizumab to oral immunotherapy for milk not only improved safety but also decreased basophil activation ([@B70]).

Food Allergy {#S10}
============

Food allergies affect about 6% of children younger than 3 years of age and 2% of adults, with 1.5 million suffering from peanut allergy in the United States. An early double-blind, placebo-controlled, randomized trial in 84 peanut allergic patients evaluated three doses of another humanized mAb against IgE, TNX-901 ([@B71]). All groups, including the placebo group, had a greater threshold of peanut tolerability, but only the high-dose TNX-901 group significantly improved from tolerating about 1/2 peanut to more than 8 peanuts at the end of therapy. Despite this 25% of the high-dose group had no improvement with therapy. A more recent attempt at a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial was designed to assess the efficacy of omalizumab in peanut allergic patients ([@B72]). Due to concern of severe anaphylactic reactions during the qualifying food challenges before therapy, only 14 patients (9 omalizumab and 4 placebo) completed treatment. Of these, four (44.4%) omalizumab-treated subjects compared to one (20%) placebo-treated subjects could tolerate \>1,000 mg peanut flour after 24 weeks, but this difference was not significant. Both of these studies suggest that omalizumab may be beneficial for food allergy, but the findings are not conclusive.

Eosinophilic Esophagitis {#S11}
========================

Eosinophilic esophagitis is another potential target for anti-IgE therapy. In two case studies of patients with eosinophilic esophagitis and multiple food allergies, the addition of omalizumab to the patient's standard therapy reduced symptoms of eosinophilic esophagitis but did not improve endoscopic and histologic changes ([@B73]). A prospective randomized, double-blind, placebo-controlled trial of omalizumab therapy monthly for 16 weeks in 30 eosinophilic esophagitis patients who were either refractory to or relapsed after topical corticosteroids found no improvements in either esophageal eosinophil counts or symptom scores ([@B74]). In an open label study, omalizumab was administered for 12 weeks to 15 subjects with long standing EoE, only 5 of the subjects had histological and clinical improvement after 3 months of treatment ([@B75]). Omalizumab induced remission of EoE was limited to those subjects with low baseline peripheral blood absolute eosinophil counts (\<450 cells/μl). Foroughi et al. examined the effect of omalizumab on assorted eosinophilic gastrointestinal disorders ([@B76]). Of the nine subjects, eight had multiple areas of eosinophilic disease with seven having at least the esophagus involved. Patients were treated with omalizumab every 2 weeks for 16 weeks. There was a non-significant decrease in eosinophils present in the duodenum and stomach while the esophageal eosinophils were unchanged. Despite this lack of histological changes, symptom scores were significantly decreased by 70% at the end of the study. No effect on T-cell function was noted in those patients treated with omalizumab ([@B77]). Overall, these studies suggest that for select patients with eosinophilic-based GI diseases anti-IgE therapy may be effective, especially those with low blood eosinophil counts.

Allergic Bronchopulmonary Aspergillosis (ABPA) {#S12}
==============================================

Allergic bronchopulmonary aspergillosis is associated with pediatric cystic fibrosis and adult asthma. One review on children with cystic fibrosis and ABPA analyzed 8 cases in 13 children ([@B78]). Treatment with omalizumab improved lung functions and reduced respiratory symptoms and systemic corticosteroid use. A Cochrane meta-analysis attempted to evaluate the effects of omalizumab for ABPA in patients with cystic fibrosis, but concluded that there were no studies that met inclusion criteria ([@B79]). A retrospective analysis of four adult stage IV ABPA patients (corticosteroid dependent) treated with omalizumab 375 mg every 2 weeks for 12 months found it was steroid sparing and reduced inflammatory markers and symptom scores, even with elevated IgE levels ([@B80]).

Nasal Polyps {#S13}
============

Nasal polyps are frequently associated with eosinophilic inflammation and local production of IgE. In a randomized, double-blind, placebo-controlled study, patients with nasal polyps and comorbid asthma were treated with either omalizumab (16) or placebo (8) for 16 weeks ([@B81]). In the omalizumab-treated group, nasal polyp size decreased by both endoscopy and CT scan assessment, regardless of allergic status. Only the omalizumab-treated patients had a significant improvement in their nasal and asthma symptom scores. A similar study of patients with nasal polyps who were continued on their medical regimen (nasal corticosteroids, leukotriene modifiers, and as needed courses of prednisone and antibiotics) found that the addition of omalizumab decreased nasal polyp size but had no significant effect on symptoms compared to the placebo group ([@B82]). A retrospective analysis of eight subjects demonstrated that omalizumab after polypectomey may reduce the severity of nasal polyp recurrence ([@B83]).

Other Diseases {#S14}
==============

A recent review on the use of omalizumab in mast cell disorders noted case studies of patients with mastocytosis, cutaneous mastocytosis, venom anaphylaxis, and mast cell activation syndrome showed improvement with omalizumab therapy ([@B84]). Case reports and small studies have noted the benefit of omalizumab treatment in Churg--Strauss Syndrome, bullous pemphigoid, Kimura's disease, aspirin-exacerbated respiratory disease, recurrent anaphylaxis, laryngeal angioedema, chronic eosinophilic pneumonia, drug allergy, and vernal keratoconjunctivitis ([@B85]--[@B93]).

Conclusion {#S15}
==========

Omalizumab is the first immune modifier to be approved for the treatment of allergic diseases (Table [1](#T1){ref-type="table"}). The excellent strength of evidence for the effectiveness of omalizumab in allergic asthma and chronic urticaria have resulted in the FDA approval for use in those diseases. While evidence points to omalizumab's effectiveness in allergic rhinitis, and as an adjunct to allergen immunotherapy, due to costs or dosing limitations omalizumab will unlikely be widely used for those instances. Large clinical trials are needed for omalizumab and other anti-IgE strategies to treat the other allergic diseases were the evidence is not as strong.

###### 

Clinical benefit with omalizumab therapy.

  ----------------- -------------------------------------------------------------------------------------------
  Strong evidence   Allergic asthmaChronic urticaria
  Good evidence     Allergic rhinitisAllergen immunotherapy (inhalants)
  Fair evidence     Atopic dermatitisFood allergyOral immunotherapy (foods)Mast cell disorders
  Weak evidence     Eosinophilic gastrointestinal diseasesAllergic bronchopulmonary aspergillosisNasal polyps
  ----------------- -------------------------------------------------------------------------------------------
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